Rajesh Sharma, MD
Interventional Pain Medicine · Boerne, TXNPI 1891004388
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Nevro Corp. at 49.2% of the total. Reporting peaked in 2021 at $26,664 and has fallen 97.2% since, to $744 in 2025. Among interventional pain medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 395 payments — averaging $224.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$44K
- Vertos Medical, Inc.$26K
- Spinal Simplicity, LLC$9K
- Abbott$7K
- Stryker$1K
- Boston Scientific$369
- plus $2K from 20 others
Across 3 payments — averaging $38,798 each. An ownership or investment interest held by the physician or an immediate family member.
- Spinal Simplicity, LLC$116K
What the payments were for
- Consulting fees$34,57039%
- Speaking & faculty fees$24,49528%
- Travel & lodging$11,89713%
- Food & beverage$16,92619%
- Education$6901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 208 | $43,614 |
| Vertos Medical, Inc. | 31 | $25,576 |
| Spinal Simplicity, LLC | 33 | $9,024 |
| Abbott | 40 | $6,552 |
| Stryker | 11 | $1,004 |
| Boston Scientific | 11 | $369 |
| Foundation Fusion Solutions, LLC | 1 | $361 |
| Globus Medical | 5 | $347 |
| Si-bone, Inc. | 4 | $267 |
| AbbVie(2 entities) | 15 | $264 |
| Pfizer | 9 | $209 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $167 |
| Medtronic(2 entities) | 5 | $122 |
| Biotronik NRO, Inc. | 3 | $111 |
| Biotronik Inc. | 1 | $108 |
| Canon Medical Systems USA, Inc. | 1 | $103 |
| Teva Pharmaceuticals USA, Inc. | 1 | $99 |
| Saluda Medical Americas, Inc. | 1 | $85 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| Scilex Pharmaceuticals Inc. | 2 | $35 |
| SPR Therapeutics, Inc | 1 | $34 |
| Averitas Pharma Inc. | 1 | $21 |
| Fidia Pharma USA Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Curonix LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnia$28,513
- mild Device Kit$25,047
- Senza$8,369
- HA MINUTEMAN G3-R$8,291
- PROCLAIM$5,592
- Senza Spinal Cord Stimulation System$3,009
- SPINEJACK$890
- iFuse Implant$148
- Minuteman$133
- SUPERION$125
- NURTEC ODT$116
- Acticor 7 VR-T DX$108
- Proclaim IPG$105
- CANON INC.$103
How this compares
$88,578 in reported general payments places this provider in the 90th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MovantikNaloxegol Oxalate | 86 | $34,750 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,054 | $25,382 |
| BelbucaBuprenorphine Hcl | 28 | $21,160 |
| LinzessLinaclotide | 14 | $11,306 |
| Lidocaine | 104 | $8,098 |
| Gabapentin | 669 | $6,145 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 210 | $5,007 |
| Morphine Sulfate ErMorphine Sulfate | 159 | $4,833 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 153 | $4,414 |
| Morphine Sulfate | 155 | $4,301 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 27 | $3,565 |
| CymbaltaDuloxetine Hcl | 13 | $3,405 |
| Naloxone Hcl | 36 | $2,435 |
| Pregabalin | 157 | $2,153 |
| Duloxetine Hcl | 187 | $2,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $16 | $21,16028 claims |
| AbbVieLinzess | $264 | $11,30614 claims |
| Lilly USA, LLCCymbalta | $12 | $3,40513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in Boerne
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.1M
- Chad StephensSouthlake$1M
- Ankur KhoslaShenandoah$277K
- Brian RichDecatur$245K
- Brian BruelHouston$219K
- Bolkar SahinlerLubbock$188K
- Timothy RatinoFort Worth$139K
- Genaro GutierrezAustin$125K
- Thomas WhiteShenandoah$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.